As evidenced by (relatively scarce) studies on blood samples obtained from cancer patients or samples of blood cell-derived solid tumours (leukaemia or lymphomas), alterations in the NRF2 interactome and/or expression may have not only prognostic relevance but also pose attractive therapeutic targets for new drugs/drug combinations. This evidence concerns the gene NFE2L2 and lymphoma.